PT  - JOURNAL ARTICLE
AU  - Delahoy, Miranda J.
AU  - Ujamaa, Dawud
AU  - Taylor, Christopher A.
AU  - Cummings, Charisse
AU  - Anglin, Onika
AU  - Holstein, Rachel
AU  - Milucky, Jennifer
AU  - O’Halloran, Alissa
AU  - Patel, Kadam
AU  - Pham, Huong
AU  - Whitaker, Michael
AU  - Reingold, Arthur
AU  - Chai, Shua J.
AU  - Alden, Nisha B.
AU  - Kawasaki, Breanna
AU  - Meek, James
AU  - Yousey-Hindes, Kimberly
AU  - Anderson, Evan J.
AU  - Openo, Kyle P.
AU  - Weigel, Andy
AU  - Teno, Kenzie
AU  - Reeg, Libby
AU  - Leegwater, Lauren
AU  - Lynfield, Ruth
AU  - McMahon, Melissa
AU  - Ropp, Susan
AU  - Rudin, Dominic
AU  - Muse, Alison
AU  - Spina, Nancy
AU  - Bennett, Nancy M.
AU  - Popham, Kevin
AU  - Billing, Laurie M.
AU  - Shiltz, Eli
AU  - Sutton, Melissa
AU  - Thomas, Ann
AU  - Schaffner, William
AU  - Talbot, H. Keipp
AU  - Crossland, Melanie T.
AU  - McCaffrey, Keegan
AU  - Hall, Aron J.
AU  - Burns, Erin
AU  - McMorrow, Meredith
AU  - Reed, Carrie
AU  - Havers, Fiona P.
AU  - Garg, Shikha
TI  - Comparison of influenza and COVID-19–associated hospitalizations among children < 18 years old in the United States — FluSurv-NET (October–April 2017–2021) and COVID-NET (October 2020–September 2021)
AID  - 10.1101/2022.03.09.22271788
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.09.22271788
4099  - http://medrxiv.org/content/early/2022/03/10/2022.03.09.22271788.short
4100  - http://medrxiv.org/content/early/2022/03/10/2022.03.09.22271788.full
AB  - Background Influenza virus and SARS-CoV-2 are significant causes of respiratory illness in children.Methods Influenza and COVID-19-associated hospitalizations among children <18 years old were analyzed from FluSurv-NET and COVID-NET, two population-based surveillance systems with similar catchment areas and methodology. The annual COVID-19-associated hospitalization rate per 100 000 during the ongoing COVID-19 pandemic (October 1, 2020–September 30, 2021) was compared to influenza-associated hospitalization rates during the 2017–18 through 2019–20 influenza seasons. In-hospital outcomes, including intensive care unit (ICU) admission and death, were compared.Results Among children <18 years old, the COVID-19-associated hospitalization rate (48.2) was higher than influenza-associated hospitalization rates: 2017–18 (33.5), 2018–19 (33.8), and 2019–20 (41.7). The COVID-19-associated hospitalization rate was higher among adolescents 12–17 years old (COVID-19: 59.9; influenza range: 12.2-14.1), but similar or lower among children 5–11 (COVID-19: 25.0; influenza range: 24.3-31.7) and 0–4 (COVID-19: 66.8; influenza range: 70.9-91.5) years old. Among children <18 years old, a higher proportion with COVID-19 required ICU admission compared with influenza (26.4% vs 21.6%; p<0.01). Pediatric deaths were uncommon during both COVID-19- and influenza-associated hospitalizations (0.7% vs 0.5%; p=0.28).Conclusions In the setting of extensive mitigation measures during the COVID-19 pandemic, the annual COVID-19-associated hospitalization rate during 2020–2021 was higher among adolescents and similar or lower among children <12 years old compared with influenza during the three seasons before the COVID-19 pandemic. COVID-19 adds substantially to the existing burden of pediatric hospitalizations and severe outcomes caused by influenza and other respiratory viruses.Summary Annual hospitalization rates and proportions of hospitalized children experiencing severe outcomes were as high or higher for COVID-19 during October 2020–September 2021 compared with influenza during the three seasons before the COVID-19 pandemic, based on U.S. population-based surveillance data.Competing Interest StatementDr. Evan Anderson reports grants from Pfizer, grants from Merck, grants from PaxVax, grants from Micron, grants from Sanofi-Pasteur, grants from Janssen, grants from MedImmune, grants from GSK, personal fees from Sanofi-Pasteur, personal fees from Pfizer, personal fees from Medscape, personal fees from Kentucky Bioprocessing, Inc, personal fees from Sanofi-Pasteur, outside the submitted work. Dr. William Schaffner reports personal fees from VBI Vaccines, outside the submitted work.Funding StatementThis work was supported by the Centers of Disease Control and Prevention through an Emerging Infections Program cooperative agreement (grant CK17-1701) and through a Council of State and Territorial Epidemiologists cooperative agreement (grant NU38OT000297-02-00).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:FluSurv-NET and COVID-NET surveillance activities were reviewed by CDC and were conducted consistent with applicable federal law and CDC policy (e.g., 45 CFR. Part 46.102(l)(2), 21 CFR part 56; 42 USC. Section 241(d); 5 USC Section 552a; 44 USC Section 3501 et seq). Sites participating in FluSurv-NET and COVID-NET obtained human subjects and ethics approvals from their respective state and local health department and academic partner Institutional Review Boards as needed.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors